NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04139317 Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% Status TERMINATED Phase PHASE2
NCT04135092 Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab Status NO_LONGER_AVAILABLE Phase N/A
NCT04134559 Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma Status RECRUITING Phase PHASE2
NCT04134325 Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase EARLY_PHASE1
NCT04129515 NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis Status WITHDRAWN Phase PHASE1/PHASE2
NCT04128696 Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Status TERMINATED Phase PHASE3
NCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04121455 Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04120454 Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT04119830 Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer Status WITHDRAWN Phase PHASE2
NCT04116775 Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Status UNKNOWN Phase PHASE2
NCT04109755 Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer Status RECRUITING Phase PHASE2
NCT04105335 A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) Status COMPLETED Phase PHASE1
NCT04104893 A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04095689 Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer Status TERMINATED Phase PHASE2
NCT04093167 Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer Status RECRUITING Phase PHASE2/PHASE3